A recent study conducted in Denmark suggests that semaglutide, a medication primarily used for weight loss, may reduce the need for triptans, commonly prescribed for migraine relief, particularly among women. The findings were shared at the European Congress on Obesity (ECO2026) but have not yet undergone peer review.
The research analyzed data from nearly 150,000 adults who began semaglutide treatment between December 2022 and June 2024, focusing on triptan usage patterns before and after the initiation of semaglutide. The results indicated that women experienced an 8% decrease in triptan use after starting the medication, while no significant change was observed among men. The largest reductions were noted in younger adults aged 18 to 35 and in those with a history of using preventive migraine medications.
Experts speculate that the effectiveness of semaglutide in reducing migraine severity may be linked to its anti-inflammatory properties and its potential to lower intracranial pressure, factors contributing to migraine development. However, the study did not find evidence that semaglutide prevents new cases of migraine from emerging.
Despite the promising results, researchers emphasize that further studies are necessary to explore the underlying mechanisms and confirm the drug's efficacy as a migraine treatment. The sex-specific differences noted in the study suggest that women may respond differently to semaglutide, possibly due to hormonal and physiological factors.
The findings contribute to a growing interest in the potential benefits of GLP-1 receptor agonists like semaglutide, indicating they may offer broader neurologic and anti-inflammatory effects beyond their primary use for weight management.